Zomedica Pharmaceuticals Corp. [AMEX: ZOM] closed the trading session at $0.14 on 08/17/20. The day’s price range saw the stock hit a low of $0.13, while the highest price level was $0.14. The company report on August 10, 2020 that Zomedica Announces Second Quarter 2020 Financial Results.
Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (“Zomedica” or “Company”), a veterinary health company, today reported consolidated financial results for the second quarter ended June 30, 2020. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America (“U.S. GAAP”).
“During the last several months, Zomedica successfully managed any effect caused by the novel coronavirus pandemic and significantly strengthened its balance sheet. As we continued the development and testing of our TRUFORMA™ platform, we successfully completed verification of three assays, and began validation studies with three university veterinary school partners,” said Robert Cohen, Interim Chief Executive Officer.
The stocks have a year to date performance of -57.25 percent and weekly performance of -10.10 percent. The stock has been moved at 5.91 percent over the last six months. The stock has performed -13.03 percent around the most recent 30 days and changed -34.94 percent over the most recent 3-months.
If compared to the average trading volume of 58.47M shares, ZOM reached to a volume of 33787796 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Zomedica Pharmaceuticals Corp. [ZOM]:
The Average True Range (ATR) for Zomedica Pharmaceuticals Corp. is set at 0.01 The Price to Book ratio for the last quarter was 1.77, with the Price to Cash per share for the same quarter was set at 0.05.
ZOM stock trade performance evaluation
Zomedica Pharmaceuticals Corp. [ZOM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.10. With this latest performance, ZOM shares dropped by -13.03% in over the last four-week period, additionally plugging by 5.91% over the last 6 months – not to mention a drop of -44.96% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZOM stock in for the last two-week period is set at 37.26, with the RSI for the last a single of trading hit 35.02, and the three-weeks RSI is set at 40.68 for Zomedica Pharmaceuticals Corp. [ZOM]. The present Moving Average for the last 50 days of trading for this stock 0.1788, while it was recorded at 0.1433 for the last single week of trading, and 0.2301 for the last 200 days.
Zomedica Pharmaceuticals Corp. [ZOM]: An insightful look at the core fundamentals
Return on Total Capital for ZOM is now -687.86, given the latest momentum, and Return on Invested Capital for the company is -687.85. Return on Equity for this stock declined to -687.85, with Return on Assets sitting at -387.30.
Reflecting on the efficiency of the workforce at the company, Zomedica Pharmaceuticals Corp. [ZOM] managed to generate an average of -$706,573 per employee.Zomedica Pharmaceuticals Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.30 and a Current Ratio set at 15.30.
Earnings per share (EPS) analysis for Zomedica Pharmaceuticals Corp. [ZOM] stock
With the latest financial reports released by the company, Zomedica Pharmaceuticals Corp. posted -0.02/share EPS, while the average EPS was predicted by analysts to be reported at -0.06/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 66.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ZOM.
Zomedica Pharmaceuticals Corp. [ZOM]: Insider Ownership positions
There are presently around $4 million, or 4.50% of ZOM stock, in the hands of institutional investors. The top three institutional holders of ZOM stocks are: CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. with ownership of 12,254,080, which is approximately 0% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 7,964,345 shares of the stock with an approximate value of $1.12 million in ZOM stocks shares; and MILLENNIUM MANAGEMENT LLC, currently with $0.14 million in ZOM stock with ownership of nearly New of the company’s market capitalization.
Positions in Zomedica Pharmaceuticals Corp. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 19 institutional holders increased their position in Zomedica Pharmaceuticals Corp. [AMEX:ZOM] by around 12,219,748 shares. Additionally, 2 investors decreased positions by around 30,700 shares, while 7 investors held positions by with 12,658,451 shares. The mentioned changes placed institutional holdings at 24,908,899 shares, according to the latest SEC report filing. ZOM stock had 14 new institutional investments in for a total of 3,986,124 shares, while 2 institutional investors sold positions of 30,700 shares during the same period.